VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/28/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has initiated a .Qu Biologics'' clinical trial in ulcerative colitis has been i ...
↧